Trials / Completed
CompletedNCT05701995
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | Specified dose on specified days. |
| OTHER | Placebo | Specified dose on specified days. |
Timeline
- Start date
- 2023-01-31
- Primary completion
- 2024-08-23
- Completion
- 2025-05-29
- First posted
- 2023-01-27
- Last updated
- 2025-09-10
- Results posted
- 2025-09-10
Locations
38 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05701995. Inclusion in this directory is not an endorsement.